OvaScience Co-Founder Recognized in Boston Globe 100’s “The Innovators” Feature

Company also named among Boston’s 50 on Fire

OvaScience Co-Founder Recognized in 100’s “The Innovators” Feature

OvaScience, Inc.Theresa McNeely, 617-299-7356Head of Corporate Communications

, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced that OvaScience Co-Founder Jonathan L. Tilly, Ph.D., has been named to 2013 “” feature.

“Dr. Tilly revolutionized the way we think about fertility, and we are pleased that has recognized his work as a driving force of innovation,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “His groundbreaking research, published on the cover of last year, showed that women have egg precursor cells found in their ovaries that can mature into fresh, young eggs. OvaScience continues to work closely with Dr. Tilly to transform this exciting discovery into new treatments for the millions of women, couples and families affected by infertility worldwide.”

On Sunday, May 19, for the twenty-fifth consecutive year, unveiled its Globe 100 list, which ranks the best-performing public companies in Massachusetts. The third annual “The Innovators” feature, part of the , recognizes the most innovative people in Massachusetts who did the most in the past year to transform a business or their community in Massachusetts, ranging from technology pioneers to inspirational leaders in the nonprofit space. In 2011, OvaScience’s Chief Scientific Officer, Scott Chappel, Ph.D., was in the Globe 100’s “The Innovators” feature for his influential role in multiple Boston start-ups.

Additionally, OvaScience was named among , which features the top 50 game-changers and innovators across all industries in the Boston area. The winners of the award were announced during a celebration at the Courthouse in Boston.

OvaScience (NASDAQ: OVAS) is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company’s patented technology is based on the discovery of egg precursor cells (EggPC), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, AUGMENT aims to improve egg quality and increase the success of in vitro fertilization (IVF). OvaScience’s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit .

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.